Elite Medical Experts Weighs in on Philips’ Recall of Breathing Machines That May Emit Toxins

On June 30, 2021, the U.S. Food and Drug Administration (FDA) alerted the public about a voluntary recall of specific Philips Respironics ventilators, BiPAP, and CPAP devices due to the risk of exposing users to particulate matter and off-gassing from polyester-based polyurethane (PE-PUR).

FDA warned that degraded PE-PUR, a component of the foam used to dampen noise and vibration, may inadvertently enter the device’s airflow pathway where it can be inhaled or ingested during therapeutic use of the machine. The recall notice followed Philips’ April 2021 announcement that they had internally “identified a quality issue in a component that is used in certain sleep and respiratory care products.”

“Direct exposure to foam particulates and chemicals can be dangerous for several reasons,” said Dr. Venktesh Ramnath, an Associate Clinical Professor of Pulmonary Medicine at UC San Diego Health. “Inhalation of particulate foam can lead to difficulty breathing and frank respiratory failure, and bacteria or fungus carried into the body can cause infection in the respiratory tract and lungs.” Regarding off-gassing, Dr. Ramnath added, “inhalation of isocyanates and other gases associated with polyurethane can cause lung irritation, and some may be carcinogenic in their own right. Prolonged exposure to these chemicals is worrisome, particularly since many people using CPAP and BiPAP already have underlying asthma and other respiratory diseases.”

“The complex issues in this recall will necessitate expert witnesses from a variety of disciplines,” says Dr. Burton Bentley II, an Emergency Medicine specialist and CEO of Elite Medical Experts. “We anticipate the need for experts in Pulmonology, Toxicology, Epidemiology, Biomedical Device Engineering, and Polymer Science. Physician experts in Occupational & Environmental Medicine will also have a role since they are frequently involved in human exposure to toxic compounds.” Regardless of the trajectory of litigation, Dr. Bentley added, “the most important thing right now is to focus on the health and safety of the millions of people affected by the recall. That means seeing a doctor and assuring that you have a safe device.”

Full article can be found here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”